Cell therapy manufacturing involves developing therapies from living cells to treat diseases like cancer, genetic disorders, and cardiovascular diseases. It utilizes cells like stem cells, dendritic cells, and T-cells to replace or regenerate human cells and tissues. These therapies are administered intravenously or through injection directly into the target tissue. The growing prevalence of cancer and other incurable diseases has increased the demand for cell therapy.
The global Cell Therapy Manufacturing Market is estimated to be valued at US$ 12.99 Bn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The expansion of cell therapy manufacturing facilities is one of the key trends driving the growth of the cell therapy manufacturing market. Many biotech and pharmaceutical companies are establishing specialized manufacturing facilities to increase production capacity and support the growing clinical pipeline of cell therapies. For instance, Juno Therapeutics, a CAR-T therapy developer acquired by Bristol-Myers Squibb, invested over $200 million in building two manufacturing facilities in Seattle and New York to produce CAR-T therapies at commercial scale. Similarly, Gilead Sciences is investing over $1 billion to construct cell therapy manufacturing facilities in the U.S. and Europe. The growing investments in building specialized facilities will help reduce manufacturing costs and meet the rising demand for commercial-stage cell therapies. This in turn is expected to accelerate the growth of the overall cell therapy manufacturing market during the forecast period.
Segment Analysis
The global cell therapy manufacturing market is dominated by the autologous segment due to the high popularity and usage of autologous stem cell transplantation. Autologous stem cells are derived from the patient's own body, eliminating risks of rejection or immunosuppression. Advancements in isolation and culture-expansion techniques have improved the clinical applicability and viability of autologous cells.
Key Takeaways
The Global Cell Therapy Manufacturing Market Demand is expected to witness high growth over the forecast period of 2023 to 2030 due to the increasing incidence of chronic diseases and rising investments in cell-based research.
Regional Analysis: North America currently dominates the global market and is expected to continue its dominance over the forecast period due to strong government funding for research activities, rising prevalence of chronic diseases, presence of many contract manufacturing organizations and biotechnology companies, and growing awareness regarding the therapeutic potential of cell therapies in the treatment of cancer and other fatal diseases.
Key players operating in the cell therapy manufacturing market are SARAHEALTH SARE, MRK Healthcare Pvt. Ltd., Amkay Products Pvt. Ltd., JIT & JIT, Kanam Latex Industries Pvt. Ltd., RFB Latex Limited, Safeshield Gloves, Amigo Surgicare Pvt. Ltd., Asma Rubber Products Pvt. Ltd., Narang Medical Limited, Phoenix Medical Technologies & Imports, Manglam Medikits Private Limited. These players are focusing on capacity expansion and new product launches to strengthen their market position.
Explore more information on this topic, Please visit-
Explore more trending article related this topic:
https://masstamilan.in/rise-of-off-price-retail-choosing-value-over-high-prices/
